Program
survodutide
Also written as “Survodutide”, “BI 456906” and “Survodutide formulation A”.
In Boehringer Ingelheim’s pipeline, GCGR/GLP1 agonist
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Fatty Liver · Liver Cirrhosis · Renal Insufficiency, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 3510 open or running | phase 3since Sep 27, 2023 | Jun 1, 2017 | Dec 8, 2026phase 1 · NCT07768813 |
- Named in Boehringer Ingelheim’s own pipeline as
Survodutide (BI 456906)
, phase 3, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 18 earlier studies, Jun 1, 2017 to Mar 8, 2024.
- Jan 19, 2023Named survodutideINNProposed as its International Nonproprietary Name in WHO's List 128 · before, BI 456906
- Apr 3, 20242 phase 1 studiesNCT06352424, NCT06352411
- Jul 1, 2024Phase 1 study in OverweightNCT06492135 · 30 enrolled · China
- Aug 20, 2024Phase 1 study in OverweightNCT06564441 · 34 enrolled · Belgium
- Oct 8, 20242 phase 3 studiesNCT06632457, NCT06632444
- Dec 19, 2024Phase 1 study in ObesityNCT06745284 · 64 enrolled · United States
- Jan 10, 2025Phase 1 study in HealthyNCT06772532 · 30 enrolled · Germany
- Jul 16, 2025Phase 1 study in HealthyNCT07071974 · 16 enrolled · Germany
- Oct 27, 2025Phase 1 study in HealthyNCT07221591 · 100 enrolled · Germany
- Feb 10, 2026Phase 1 study in ObesityNCT07413913 · 56 enrolled · Germany
- Aug 5, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07754461 · 600 planned · United States, Australia, Canada and more
- Aug 12, 2026Phase 1 study in ObesityNCT07768813 · 44 enrolled · Germany
- Sep 25, 20263 phase 3 studies in ObesityNCT07850063, NCT07850050, NCT07855900
- Oct 27, 2026Primary completion moved from 2028-06-25 to 2029-11-06Date moved laterphase 3 · +16 months · NCT07855900
- Nov 9, 2026Phase 1 study in ObesityNCT07940244 · 80 planned · Germany
Ahead
- Nov 1, 2026Primary completion: phase 1 study in ObesityNCT06745284
- Dec 8, 2026Primary completion: phase 1 study in ObesityNCT07768813
- Jan 6, 2027Primary completion: phase 1 study in ObesityNCT05202353
- Oct 31, 2027Primary completion: phase 1 study in ObesityNCT07940244
TargetBeta
“GCGR/GLP1 agonist”the company's pipeline, read by Claude · source
“Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| DR10624rule | Huadong Medicine | phase 3 | 6 |
| efinopegdutide | Johnson & Johnson | phase 2 | 15 |
| AZD9550 | AstraZeneca | phase 2 | 7 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07940244Obesity · Germany | 1 | Not yet recruiting | Oct 31, 2027 | 80 |
| NCT07855900Obesity · United States, Germany, Spain and more | 3 | Recruiting | Nov 6, 2029 | 350 |
| NCT07850063Obesity · United States, China, Germany and more | 3 | Not yet recruiting | Apr 29, 2029 | 600 |
| NCT07850050Obesity · United States, Germany, Spain and more | 3 | Recruiting | Jul 26, 2028 | 600 |
| NCT07768813Obesity · Germany | 1 | Active, not recruiting | Dec 8, 2026 | 44 |
| NCT07754461Diabetes Mellitus, Type 2 · United States, Australia, Canada and more | 3 | Recruiting | Jan 17, 2028 | 600 |
| NCT07413913Obesity · Germany | 1 | Completed | May 28, 2026 | 56 |
| NCT07221591Healthy · Germany | 1 | Completed | Jul 28, 2026 | 100 |
| NCT07071974Healthy · Germany | 1 | Completed | Oct 7, 2025 | 16 |
| NCT06772532Healthy · Germany | 1 | Completed | May 29, 2025 | 30 |
| NCT06745284Obesity · United States | 1 | Active, not recruiting | Nov 1, 2026 | 64 |
| NCT06632457Metabolic Dysfunction Associated Steatohepatitis · United States, Argentina, Australia and more | 3 | Recruiting | Jun 5, 2029 | 1,590 |
| NCT06632444Liver Cirrhosis · United States, Argentina, Australia and more | 3 | Recruiting | Dec 27, 2031 | 1,800 |
| NCT06564441Overweight · Belgium | 1 | Completed | Dec 16, 2025 | 34 |
| NCT06492135Overweight · China | 1 | Completed | Apr 15, 2025 | 30 |
| NCT06352424Obesity · Germany | 1 | Completed | Feb 24, 2025 | 23 |
| NCT06352411Renal Insufficiency · Germany | 1 | Completed | Sep 16, 2025 | 42 |
| NCT06309992Obesity · United States, Spain | 3 | Completed | Oct 9, 2025 | 218 |
| NCT06214741Obesity · China | 3 | Completed | Jul 29, 2025 | 307 |
| NCT06200467Overweight · Germany | 1 | Completed | Oct 22, 2025 | 110 |
| NCT06176365Obesity · Japan | 3 | Completed | Dec 3, 2025 | 274 |
| NCT06077864Obesity · United States, Argentina, Australia and more | 3 | Completed | Jun 1, 2026 | 5,530 |
| NCT06066528Obesity · United States, Australia, Belgium and more | 3 | Completed | Dec 12, 2025 | 755 |
| NCT06066515Obesity · United States, Australia, Belgium and more | 3 | Completed | Dec 2, 2025 | 726 |
| NCT05896384Healthy · Germany | 1 | Completed | Feb 14, 2025 | 32 |
| NCT05751226Obesity · Germany | 1 | Completed | Aug 1, 2024 | 88 |
| NCT05421338Healthy · Netherlands | 1 | Completed | Nov 17, 2022 | 6 |
| NCT05296733Liver Diseases · United States, Germany, Hungary and more | 1 | Completed | Dec 29, 2023 | 82 |
| NCT05202353Obesity · Netherlands | 1 | Active, not recruiting | Jan 6, 2027 | 29 |
| NCT04771273Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more | 2 | Completed | Nov 9, 2023 | 295 |
| NCT04667377Obesity · United States, Australia, Belgium and more | 2 | Completed | Sep 15, 2022 | 387 |
| NCT04384081Healthy · Japan | 1 | Completed | Nov 17, 2020 | 37 |
| NCT04153929Diabetes Mellitus, Type 2 · United States, Australia, Austria and more | 2 | Completed | Oct 8, 2021 | 413 |
| NCT03591718Obesity · Germany | 1 | Completed | Apr 20, 2020 | 131 |
| NCT03175211Healthy · Germany | 1 | Completed | Feb 19, 2018 | 20 |
How it is read
Names in the registry
- “Survodutide”, 12 entries
- “BI 456906”, 12 entries
- “survodutide”, 5 entries
- “Survodutide formulation A”, 3 entries
- “Survodutide formulation B2”, 2 entries
Conditions, from the studies’ own filings
- Obesity, 21 studies
- Diabetes Mellitus, Type 2, 2 studies
- Fatty Liver, 1 study
- Liver Cirrhosis, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.